Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5

Author:

Kawasuji Hitoshi1,Morinaga Yoshitomo23ORCID,Tani Hideki24ORCID,Saga Yumiko24,Yamada Hiroshi2,Yoshida Yoshihiro1,Takegoshi Yusuke1,Kaneda Makito1,Murai Yushi1,Kimoto Kou1,Ueno Akitoshi1,Miyajima Yuki1,Nagaoka Kentaro1,Ono Chikako56,Matsuura Yoshiharu56,Niimi Hideki37,Yamamoto Yoshihiro13

Affiliation:

1. Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan

2. Department of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan

3. Clinical and Research Center for Infectious Diseases, Toyama University Hospital, Toyama, Japan

4. Department of Virology, Toyama Institute of Health, Toyama, Japan

5. Laboratory of Virus Control, Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan

6. Laboratory of Virus Control, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan

7. Department of Clinical Laboratory and Molecular Pathology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan

Abstract

Although Omicron BA.1-containing bivalent vaccines have been authorized, real-world data validating their safety and antibody responses remain scarce. We conducted a prospective longitudinal study to assess the safety, immunogenicity, and reactogenicity of the second booster dose with the Omicron BA.1 bivalent vaccine in health care workers.

Funder

Toyama Pharmaceutical Valley Development Consortium

Morinomiyako Medical Research Roundation

Hokuriku Bank grant-in-aid for Young Scientists

Japan Society for the Promotion of Science

Japan Agency for Medical Research and Development

Kurozumi Medical Foundation

University of Toyama

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3